Tecan and Enigma Diagnostics Sign Licence and Collaboration Agreement

The Tecan Group and Enigma Diagnostics Limited have signed a licence and collaboration agreement, that provides Tecan with access to specific Enigma intellectual property that is used in Enigma´s fully automated, molecular diagnostic system, the Enigma® ML.

The licence enables Tecan to further expand its growing OEM partnering business and develop a next generation molecular diagnostics platform for a potential OEM partner. The envisaged integrated solution includes enabling consumables and is targeted at central laboratories with the goal to provide a unique combination of features such as, random sample access, complete automation from raw sample to result, a small footprint and a rapid time to result.

Thomas Bachmann, CEO of Tecan, said: 'We are delighted to have signed this licence agreement with Enigma for their innovative sample preparation and thermocycling technology. The licence provides us with the opportunity to approach a potential OEM partner with our concept of an integrated solution for molecular diagnostics that includes a unique instrument as well as enabling consumables.

The licence agreement builds on our existing agreement with Enigma that we signed in February 2010 for the manufacturing and supply of Enigma® ´s ML point-of-care molecular diagnostics instruments.'

John McKinley, Chairman and CEO of Enigma, said: 'We are very pleased to sign this significant agreement which extends an already strong partnership with Tecan. It demonstrates the capability of Enigma´s sample preparation and thermocycling technology to generate a pipeline of next generation molecular diagnostic instruments covering high throughput, central laboratory to point of care settings.'